Pressure BioSciences’ (OTCQB: PBIO) patented Ultra Shear Technology(TM) (“UST”) platform has produced stable, high-quality neem oil nanoemulsions. The nanoemulsions are designed to provide safe, natural, and environmentally friendly pesticides, which can be used to mitigate agricultural losses and decrease the spread of disease by insects. These nanoemulsions combine with water and then remain suspended for months, in the process having a protective impact on ingredients that would typically deteriorate. Neem oil is a common preventative treatment for malaria, but dosing has been a challenge in the past. PBIO’s breakthrough development could provide solutions to that challenge. In addition, the nanoemulsions may also be used for other oil-based applications, opening the door to additional uses and possibilities for Pressure BioSciences, which is a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics, cosmeceuticals, nutraceuticals, and food & beverage industries. Mr. Richard T. Schumacher, President & CEO of PBI, commented: “Discussions continue with prospective partners worldwide who are interested in using the UST platform in the production and commercialization of their oil-based products for a multitude of applications,” said Pressure BioSciences president and CEO Richard T. Schumacher in the press release. “In addition, we continue to explore opportunities where our UST platform can improve the effectiveness and competitiveness of our own products, such as the organic, eco-friendly products we plan to sell through our new, wholly-owned subsidiary PBI Agrochem. This includes our internally-developed neem oil extract ($2.04 billion market by
2022). Such products offer the tantalizing opportunity for commercialization into both wholesale and retail marketplaces, which we are actively considering for PBI Agrochem.”
To view the full press release, visit
https://ibn.fm/a8erS
About Pressure BioSciences Inc.
Pressure BioSciences is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. PBIO’s products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) (“PCT”) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control biomolecular interactions safely and reproducibly (e.g., cell lysis, biomolecule extraction). The company’s primary focus is the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil and plant biology, forensics and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of the company’s pressure-based technologies in the following areas: (1) the use of PBIO’s recently acquired, patented technology from BaroFold Inc. to allow entry into the biopharma contract services sector and (2) the use of PBIO’s recently patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to prepare higher-quality, homogenized, extended shelf-life or room-temperature, stable, low-acid liquid foods that cannot be effectively preserved using existing nonthermal technologies. For more information about the company, visit
www.PressureBioSciences.com.
NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at
http://ibn.fm/PBIO
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork.